arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

PRECIGEN, INC.

PGEN
$4.17 ▼ -0.89 (-17.59%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

PRECIGEN, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield —
Revenue Growth 146.7%
Op. Margin None
ROIC -96.9% ↗
FCF / Share $-0.29 →
Trailing P/E —
Price / Book 70.6x
FCF Yield —
Debt / Equity 4.46
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$9.68M
↑ +146.7% —
Net Income Profit after all expenses
$-250.64M
↓ -98.6% —
Operating Margin Operating profit as % of sales
-314.9%
↓ -427.5% —
FCF / Share Free cash flow per share
$-0.29
— -0.1% —
Long-Term Debt Long-term obligations
$93.17M
— —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Financial Health ↑
13
Cash Quality ↓
34

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 58 quarters